Apogee Therapeutics (APGE) Share-based Compensation (2023 - 2026)
Apogee Therapeutics (APGE) posted quarterly Share-based Compensation of $256000.0 for Q1 2026, down 97.7% year-over-year from $11.1 million in Q1 2025, and down 97.84% quarter-over-quarter from $11.9 million in Q3 2025.
Apogee Therapeutics (APGE) Share-based Compensation (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Share-based Compensation for 4 consecutive years, with $256000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 97.7% year-over-year to $256000.0; the TTM figure through Mar 2026 stood at $23.5 million (down 22.45% YoY), while the FY2025 annual figure was $110.1 million, down 18.14% from the prior year.
- Share-based Compensation declined to $256000.0 in Q1 2026 per APGE's latest filing, from $11.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $180.5 million in Q4 2023 and bottomed at $256000.0 in Q1 2026.
- Historically, Share-based Compensation has averaged $20.2 million across 4 years, with a median of $5.8 million in 2024.
- Annual changes were most pronounced in 2024 — Share-based Compensation soared 411.95% — and 2026, when it sank 97.7%.
- Apogee Therapeutics' Share-based Compensation stood at $180.5 million in 2023, then tumbled by 95.78% to $7.6 million in 2024, then soared by 56.09% to $11.9 million in 2025, then slumped by 97.84% to $256000.0 in 2026.
- Business Quant data shows APGE's Share-based Compensation at $256000.0 in Q1 2026, $11.9 million in Q3 2025, and $11.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 168.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.30 Mn |
| Jun 30, 2026 | 168.30 Mn |
| Mar 31, 2026 | 256,000.00 |
| Mar 31, 2026 | 256,000.00 |
| Sep 30, 2025 | 11.88 Mn |
| Sep 30, 2025 | 11.88 Mn |
| Jun 30, 2025 | 11.34 Mn |
| Jun 30, 2025 | 11.34 Mn |
| Mar 31, 2025 | 11.13 Mn |
| Mar 31, 2025 | 11.13 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Dec 31, 2024 | 7.61 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Mar 31, 2024 | 4.19 Mn |
| Mar 31, 2024 | 4.19 Mn |
| Dec 31, 2023 | 180.51 Mn |
| Dec 31, 2023 | 180.51 Mn |